Archive for the ‘University of Rochester spinoffs’ Category

iCardiac (Rochester) Announces Award of a Global Phase III Cardiac Safety Study (10/21/2010)

November 1, 2010

iCardiac Technologies develops and markets drug safety technology, which was originally developed at the University of Rochester Heart Research Follow-Up Program under Dr. Jean-Philippe Couderc, who is the company’s CTO.

iCardiac Technologies, Inc., a provider of next generation cardiac core lab services, announced today that it has been awarded a centralized ECG services contract for a global multi-site Phase III study. The study will be conducted leveraging iCardiac’s next generation solutions for cost-effective centralization of digital ECG data as well as COMPAS technology platform for ECG data analysis. read more